XENE Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Xenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

BURNABY, British Columbia, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 9-12, 2023.

Company Presentation Details:

Date:Monday, January 9, 2023
  
Time:7:30 am Pacific Time (10:30 am Eastern Time)
  
Presenters:Ian Mortimer, President and CEO

A live webcast of the company presentation will be available on the “” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit .

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:

Jodi Regts

Xenon Pharmaceuticals Inc.

Phone: 604.484.3353

Email:



EN
04/01/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Xenon Pharmaceuticals Inc

 PRESS RELEASE

Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in...

Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-term efficacy and safety data from X-TOLE open-label extension study of azetukalner, as well as real-world data regarding the burden of titration and need for no-titration options in epilepsy VANCOUVER, British Columbia and BOSTON, MA, April 07, 2026 (GLOBE NEWSWIRE) -- Xenon ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch